Immuno-oncology is an emerging field that has revolutionized cancer treatment. Most
immunomodulatory strategies focus on enhancing T cell responses, but there has been a …

Calreticulin (CRT) is a pleiotropic and highly conserved molecule that is mainly localized in
the endoplasmic reticulum. Recently, CRT has gained special interest for its functions …

Background The calreticulin (CALR) exon 9 mutations that are identified in 20% of patients
with Philadelphia chromosome negative chronic myeloproliferative neoplasms (MPN) …

Infections are a common complication in patients with many hematologic malignancies,
however, whether patients with myeloproliferative neoplasms (MPN) also are at an …

The Philadelphia-negative myeloproliferative neoplasms (MPNs) are malignancies of the
hematopoietic stem cell (HSC) arising as a consequence of clonal proliferation driven by …

Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has
recently been associated with the occurrence of second primary malignancies (SPMs) …

The last decade has been very important for the quantity of preclinical information obtained
regarding chronic myeloproliferative neoplasms (MPNs) and the following will be dedicated …

Infections represent one of the major concerns regarding the utilization of ruxolitinib (RUX)
in patients with myelofibrosis. With the aim to investigate epidemiology, outcome and risk …

Myelofibrosis (MF) is characterized by chronic inflammation and hyper-activation of the JAK-
STAT pathway. Infections are one of the main causes of morbidity/mortality. Therapy with …

Immunotherapies have revolutionized cancer treatment over the last 20 years. They aim
either to boost immune cell activation or decrease immune cell inhibition, to improve control …